About Treovir

The Science

Our Team

Glioblastoma is a leading cause of cancer-related death in pediatric patients.

There are no approved therapies for Pediatric Brain tumors.

Current therapies are ineffective and have devastating side effects.

Treovir’s G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects.


Success Story

University of Alabama at Birmingham and Children’s of Alabama


Nick Tasoglou came to UAB and Children’s of Alabama after being diagnosed with a brain tumor. 5 months after G207 treatment, scans showed holes forming in the tumor at the G207 injection sites. More than 4 years after a single G207 treatment, with no other therapies, Nick has shown a strong response.

Together We Can Strive To

Change the course of brain tumor therapies

Improve survival rates and quality of life

Provide Hope

Our Common Goal

Treovir will launch a Phase 2 clinical study for G207 in 2021 that is designed to seek
market approval to treat pediatric patients with recurrent pediatric gliomblastoma.


Check Out What's New

Treovir collaborates with a number of institutions for the development of G207.